Publication:
Prophylactic Acetylcysteine Usage for Prevention of Contrast Nephropathy after Coronary Angiography

dc.contributor.authorGulel, O
dc.contributor.authorKeles, T
dc.contributor.authorEraslan, H
dc.contributor.authorAydogdu, S
dc.contributor.authorDiker, E
dc.contributor.authorUlusoy, V
dc.date.accessioned2020-06-21T15:30:26Z
dc.date.available2020-06-21T15:30:26Z
dc.date.issued2005
dc.departmentOMÜen_US
dc.department-temp19 Mayis Univ, Dept Cardiol, Fac Med, Samsun, Turkey -- Ataturk Educ & Res Hosp, Cardiol Clin, Ankara, Turkey -- Numune Educ & Res Hosp, Cardiol Clin, Ankara, Turkey --en_US
dc.description.abstractRadiographic contrast agents can cause acute decrease in renal functions. It is thought that anti-oxidant acetylcysteine can prevent contrast nephropathy. Fifty patients planned to undergo elective diagnostic coronary angiography with serum creatinine values above 1.3 mg/dL were included in the study. Acetylcysteine was given orally at a dose of 600 mg twice daily, on the day before and on the day of administration of contrast agent in the acetylcysteine group (n = 25). Acetylcysteine was not given to the control group (n = 25). Saline (0.9%) was given intravenously at a rate of 1 mL/kg/h for 12 hours before and 12 hours after administration of contrast agent. Contrast nephropathy was detected in 3 of 25 patients (12%) in the acetyleysteine group and 2 of 25 patients (8%) in the control group (P > 0.05). Contrast nephropathy was developed in 2 of 4 patients (50%) with baseline serum creatinine concentrations above 2.5 mg/dL, whereas it was developed in only 3 of 46 patients (6.5%) with baseline serum creatinine concentrations below 2.5 mg/dL (P = 0.04). It was detected that in patients planned to undergo elective diagnostic coronary angiography with renal dysfunction, oral acetylcysteine and hydration before the procedure was not more effective than hydration alone in the prevention of contrast nephropathy. High baseline serum creatinine values were detected as a risk factor for development of contrast nephropathy.en_US
dc.identifier.doi10.1097/01.fjc.0000176730.59443.dd
dc.identifier.endpage467en_US
dc.identifier.issn0160-2446
dc.identifier.issn1533-4023
dc.identifier.issue4en_US
dc.identifier.pmid16160598
dc.identifier.startpage464en_US
dc.identifier.urihttps://doi.org/10.1097/01.fjc.0000176730.59443.dd
dc.identifier.urihttps://hdl.handle.net/20.500.12712/20923
dc.identifier.volume46en_US
dc.identifier.wosWOS:000235094000010
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.journalJournal of Cardiovascular Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcetylcysteineen_US
dc.subjectContrast Nephropathyen_US
dc.subjectCoronary Angiographyen_US
dc.titleProphylactic Acetylcysteine Usage for Prevention of Contrast Nephropathy after Coronary Angiographyen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files